These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34384826)

  • 1. Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.
    Lai V; Neshat SY; Rakoski A; Pitingolo J; Doloff JC
    Adv Drug Deliv Rev; 2021 Dec; 179():113920. PubMed ID: 34384826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metronomic chemotherapy and nanocarrier platforms.
    Abu Lila AS; Ishida T
    Cancer Lett; 2017 Aug; 400():232-242. PubMed ID: 27838415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
    Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
    Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.
    Biziota E; Mavroeidis L; Hatzimichael E; Pappas P
    Cancer Lett; 2017 Aug; 400():243-251. PubMed ID: 28017892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
    Doloff JC; Chen CS; Waxman DJ
    Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
    Wu J; Waxman DJ
    Cancer Lett; 2018 Apr; 419():210-221. PubMed ID: 29414305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
    Chen CS; Doloff JC; Waxman DJ
    Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metronomic chemotherapy and immunotherapy in cancer treatment.
    Chen YL; Chang MC; Cheng WF
    Cancer Lett; 2017 Aug; 400():282-292. PubMed ID: 28189534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metronomic therapy: chemotherapy revisited.
    Noronha V; Krishna MV; Patil V; Joshi A; Banavali SD; Prabhash K
    Indian J Cancer; 2013; 50(2):142-8. PubMed ID: 23979206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metronomic chemotherapy and anti-angiogenesis: can upgraded pre-clinical assays improve clinical trials aimed at controlling tumor growth?
    Norrby K
    APMIS; 2014 Jul; 122(7):565-79. PubMed ID: 24164171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package.
    Bahl A; Bakhshi S
    Indian J Pediatr; 2012 Dec; 79(12):1617-22. PubMed ID: 22544675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.
    Kwak G; Jo SD; Kim D; Kim H; Kim MG; Kim K; Kwon IC; Kim SH
    J Control Release; 2017 Dec; 267():203-213. PubMed ID: 28823674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
    Pietras K; Hanahan D
    J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer.
    Tas F; Duranyildiz D; Soydinc HO; Cicin I; Selam M; Uygun K; Disci R; Yasasever V; Topuz E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):721-5. PubMed ID: 17554539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metronomic chemotherapy: new rationale for new directions.
    Pasquier E; Kavallaris M; André N
    Nat Rev Clin Oncol; 2010 Aug; 7(8):455-65. PubMed ID: 20531380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
    Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
    Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.